(TheNewswire)
Sernova’s CellPouch platform and cell therapy expertise being used in multiplecollaborations with global pharmaceutical companies
LONDON, ONTARIO – TheNewswire - January 28, 2021 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE:PSH ), a leading clinical-stageregenerative medicine therapeutics company, announced today that ithas entered into multiple research collaboration agreements withglobal pharmaceutical companies.
Sernova is deploying its in-house cell therapyexpertise and patent-protected Cell Pouch technologies in combinationwith proprietary therapeutic cell assets designated by thepharmaceutical collaborators. Further details of these agreements willbe kept confidential for strategic reasons. The collaborators haverequested anonymity.
“The research collaborationsfollow the ongoing clinical success of Sernova’s Cell Pouchtechnologies in diabetes, and reflect the value and evolvingrecognition of our technologies and cell therapy platform,” said Dr.Philip Toleikis, President and CEO of Sernova Corp. “ Theseimportant partnerships with leaders in the pharma industry build uponSernova’s business strategy to develop a portfolio of products torealize the full potential of Sernova’s regenerative medicineplatform by extending and broadening its application to newtherapeutic areas and modalities. Sernova’s goal is to providepeople with a functional cure for multiple chronic and rarediseases.”
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease. The CellPouch, along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase I/IIstudy at the University of Chicago.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutictechnologies using a medical device and immune protected therapeuticcells (i.e., human donor cells, corrected human cells and stemcell-derived cells) to improve the treatment and quality of life ofpeople with chronic metabolic diseases such as insulin-dependentdiabetes, blood disorders including hemophilia, and other diseasestreated through replacement of proteins or hormones missing or inshort supply within the body. For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.